Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study

Empirical dose intensification and therapeutic drug monitoring [TDM] of infliximab [IFX] trough levels [ITLs] and antibody to infliximab [ATI] assays are recognized approaches for managing loss of response [LoR] in patients with inflammatory bowel disease [IBD]. The aim of the study was to compare t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of Crohn's and colitis 2018-08, Vol.12 (9), p.1079-1088
Hauptverfasser:	Guidi, Luisa, Pugliese, Daniela, Tonucci, Tommaso Panici, Berrino, Alexandra, Tolusso, Barbara, Basile, Michele, Cantoro, Laura, Balestrieri, Paola, Civitelli, Fortunata, Bertani, Lorenzo, Marzo, Manuela, Felice, Carla, Gremese, Elisa, Costa, Francesco, Viola, Franca, Cicala, Michele, Kohn, Anna, Gasbarrini, Antonio, Rapaccini, Gian Lodovico, Ruggeri, Matteo, Armuzzi, Alessandro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Algorithms Child Cohort Studies Cost-Benefit Analysis Drug Monitoring - economics Female Gastrointestinal Agents - therapeutic use Humans Inflammatory Bowel Diseases - drug therapy Infliximab - therapeutic use Male Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!